Abstract
Background and purpose
Approximately, 50% of myasthenia gravis (MG) patients initially present with purely ocular symptoms. Of these, about 60% will develop secondary generalized MG, typically within 2 years. Risk factors for secondary generalization are still controversial. In this study, we reviewed clinical parameters, thymic pathologies and medical treatments of MG patients with purely ocular symptoms at onset to investigate risk factors for secondary generalization.
Methods
In this monocentric retrospective study, we reviewed consecutive patients who underwent robotic thymectomy between January 2003 and October 2017 in Charite Universitaetsmedizin Berlin. We used univariate and multivariate Cox proportional hazards regression models to identify factors associated with secondary generalization. Survival curves were plotted using Kaplan–Meier method and log-rank tests were performed to analyze the association between corticosteroids use and secondary generalization in subgroups defined by anti-AChR antibody status and thymic pathology.
Results
One hundred and eighty of 572 MG patients who underwent robotic thymectomy were eligible for inclusion, of whom 110 (61.1%) developed a secondary generalized MG over a mean follow-up time of 23.6 months. The presence of a thymoma (HR 1.659, 95% CI (1.52–2.617), P = 0.029) was the only risk factor for secondary generalization in our series. Treating with corticosteroids was associated with a lower conversion rate in ocular myasthenia patients with thymic hyperplasia (n = 55, P = 0.028), but not with other thymic pathologies including thymoma and normal or atrophic thymus.
Conclusions
The conversion rate in ocular myasthenia was high in our series, predicted by the presence of a thymoma. Our findings suggest that corticosteroids can prevent secondary generalization in ocular myasthenia patients with thymic hyperplasia, which requires further research.
Similar content being viewed by others
References
Gilhus NE, Skeie GO, Romi F, Lazaridis K, Zisimopoulou P, Tzartos S (2016) Myasthenia gravis—autoantibody characteristics and their implications for therapy. Nat Rev Neurol 12:259–268
Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14:1023–1036
Querol L, Illa I (2013) Myasthenia gravis and the neuromuscular junction. Curr Opin Neurol 26:459–465
Carr AS, Cardwell CR, McCarron PO, McConville J (2010) A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol 10:46
Bever CT Jr, Aquino AV, Penn AS, Lovelace RE, Rowland LP (1983) Prognosis of ocular myasthenia. Ann Neurol 14:516–519
Weinberg DA, Lesser RL, Vollmer TL (1994) Ocular myasthenia: a protean disorder. Surv Ophthalmol 39:169–210
Golnik KC, Pena R, Lee AG, Eggenberger ER (1999) An ice test for the diagnosis of myasthenia gravis. Ophthalmology 106:1282–1286
Smith SV, Lee AG (2017) Update on ocular myasthenia gravis. Neurol Clin 35:115–123
Haines SR, Thurtell MJ (2012) Treatment of ocular myasthenia gravis. Curr Treat Options Neurol 14:103–112
Kerty E, Elsais A, Argov Z, Evoli A, Gilhus NE (2014) EFNS/ENS Guidelines for the treatment of ocular myasthenia. Eur J Neurol 21:687–693
Kaminski HJ, Daroff RB (2000) Treatment of ocular myasthenia: steroids only when compelled. Arch Neurol 57:752–753
Kupersmith MJ, Moster M, Bhuiyan S, Warren F, Weinberg H (1996) Beneficial effects of corticosteroids on ocular myasthenia gravis. Arch Neurol 53:802–804
Mee J, Paine M, Byrne E, King J, Reardon K, O’Day J (2003) Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J Neuroophthalmol 23:251–255
Liu Z, Feng H, Yeung SC, Zheng Z, Liu W, Ma J, Zhong FT, Luo H, Cheng C (2011) Extended transsternal thymectomy for the treatment of ocular myasthenia gravis. Ann Thorac Surg 92:1993–1999
Mineo TC, Ambrogi V (2013) Outcomes after thymectomy in class I myasthenia gravis. J Thorac Cardiovasc Surg 145:1319–1324
Roberts PF, Venuta F, Rendina E, De Giacomo T, Coloni GF, Follette DM, Richman DP, Benfield JR (2001) Thymectomy in the treatment of ocular myasthenia gravis. J Thorac Cardiovasc Surg 122:562–568
Sussman J, Farrugia ME, Maddison P, Hill M, Leite MI, Hilton-Jones D (2015) Myasthenia gravis: association of British Neurologists’ management guidelines. Pract Neurol 15:199–206
Nakamura H, Taniguchi Y, Suzuki Y, Tanaka Y, Ishiguro K, Fukuda M, Hara H, Mori T (1996) Delayed remission after thymectomy for myasthenia gravis of the purely ocular type. J Thorac Cardiovasc Surg 112:371–375
Hong YH, Kwon SB, Kim BJ, Kim BJ, Kim SH, Kim JK, Park KS, Park KJ, Sung JJ, Sohn EH, Lee YB, Jeong D, Joo IS, Choi BO, Choi YC, Korean Research Group for Neuromuscular D (2008) Prognosis of ocular myasthenia in Korea: a retrospective multicenter analysis of 202 patients. J Neurol Sci 273:10–14
Nagia L, Lemos J, Abusamra K, Cornblath WT, Eggenberger ER (2015) Prognosis of ocular myasthenia gravis: retrospective multicenter analysis. Ophthalmology 122:1517–1521
Farrugia ME, Cleary M, Carmichael C (2017) A retrospective study of acetylcholine receptor antibody positive ocular myasthenia in the West of Scotland. J Neurol Sci 382:84–86
Wang LL, Zhang Y, He ML (2015) Clinical features and prognosis of ocular myasthenia gravis patients with different phenotypes. Chin Med J (Engl) 128:2682–2684
Huang X, Li Y, Feng H, Chen P, Liu W (2018) Clinical characteristics of juvenile myasthenia gravis in Southern China. Front Neurol 9:77
Teo KY, Tow SL, Haaland B, Gosavi TD, Jing-Liang L, Yew Long LO, Milea D (2018) Low conversion rate of ocular to generalized myasthenia gravis in Singapore. Muscle Nerve 57:756–760
Mazzoli M, Ariatti A, Valzania F, Kaleci S, Tondelli M, Nichelli PF, Galassi G (2018) Factors affecting outcome in ocular myasthenia gravis. Int J Neurosci 128:15–24
Kamarajah SK, Sadalage G, Palmer J, Carley H, Maddison P, Sivaguru A (2018) Ocular presentation of myasthenia gravis: a natural history cohort. Muscle Nerve 57:622–627
Aguirre F, Villa AM (2018) Prognosis of ocular myasthenia gravis in an Argentinian population. Eur Neurol 79:113–117
Wong SH, Huda S, Vincent A, Plant GT (2014) Ocular myasthenia gravis: controversies and updates. Curr Neurol Neurosci 14:421
Grob D (1953) Course and management of myasthenia gravis. J Am Med Assoc 153:529–532
Sommer N, Sigg B, Melms A, Weller M, Schepelmann K, Herzau V, Dichgans J (1997) Ocular myasthenia gravis: response to long-term immunosuppressive treatment. J Neurol Neurosurg Psychiatry 62:156–162
Kupersmith MJ, Latkany R, Homel P (2003) Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol 60:243–248
Monsul NT, Patwa HS, Knorr AM, Lesser RL, Goldstein JM (2004) The effect of prednisone on the progression from ocular to generalized myasthenia gravis. J Neurol Sci 217:131–133
Wong SH, Petrie A, Plant GT (2016) Ocular myasthenia gravis: toward a risk of generalization score and sample size calculation for a randomized controlled trial of disease modification. J Neuroophthalmol 36:252–258
Allen JA, Scala S, Jones HR (2010) Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis. Muscle Nerve 41:379–384
Kupersmith MJ (2009) Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. J Neurol 256:1314–1320
Mittal MK, Barohn RJ, Pasnoor M, McVey A, Herbelin L, Whittaker T, Dimachkie M (2011) Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response. J Clin Neuromuscul Dis 13:46–52
Zach H, Cetin H, Hilger E, Paul A, Wuschitz B, Jung R, Auff E, Zimprich F (2013) The effect of early prednisolone treatment on the generalization rate in ocular myasthenia gravis. Eur J Neurol 20:708–713
Benatar M, McDermott MP, Sanders DB, Wolfe GI, Barohn RJ, Nowak RJ, Hehir M, Juel V, Katzberg H, Tawil R, Muscle Study G (2016) Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): a randomized, controlled trial. Muscle Nerve 53:363–369
Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP, Beeson D, Willcox N, Vincent A (2008) IgG1 antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis. Brain 131:1940–1952
Acknowledgements
We are thankful to Dr. Alexandra McAleenan, Senior Research Associate in Research Synthesis, University of Bristol for her assistance in editing this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
The authors declare no financial or other conflicts of interest.
Ethical standards
This research was approved by Ethics Committee of Charite Universitaetsmedizin Berlin (Berlin, Germany).
Informed consent
All patients gave their informed consent prior to their inclusion in the study.
Rights and permissions
About this article
Cite this article
Li, F., Hotter, B., Swierzy, M. et al. Generalization after ocular onset in myasthenia gravis: a case series in Germany. J Neurol 265, 2773–2782 (2018). https://doi.org/10.1007/s00415-018-9056-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-018-9056-8